Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Jacqueline Armstrong

Nurse Practitioner, Psychiatric/Mental Health Wilmington, DE Nurse Practitioner

NPI 1619504867 CMS profile 11235575

501 W 14Th St Ste 1E40, Wilmington, DE 19801

Open in the dashboard

General payments

$5,749

322 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jacqueline Armstrong of Wilmington, DE is reported in the CMS Open Payments database as having received $5,749 across 322 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 93rd percentile of Nurse Practitioner, Psychiatric/Mental Health profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,092 49
2024 General $1,728 96
2023 General $1,453 85
2022 General $875 57
2021 General $601 35

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jacqueline Armstrong
  • Nurse Practitioner, Psychiatric/Mental Health median
  • Middle half of Nurse Practitioner, Psychiatric/Mental Health
  • National median

In program year 2025, general payments to Jacqueline Armstrong were reported at $1,092. Among 26,152 Nurse Practitioner, Psychiatric/Mental Health profiles paid that year, the median was $258 and the middle half received between $93 and $764.

Show as a table
Year Jacqueline Armstrong Nurse Practitioner, Psychiatric/Mental Health median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $601 $166 $54–$482 $132
2022 $875 $195 $66–$559 $149
2023 $1,453 $233 $82–$673 $160
2024 $1,728 $236 $84–$688 $164
2025 $1,092 $258 $93–$764 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Axsome Therapeutics, Inc. $694 33 payments
  2. AbbVie, Inc. $561 35 payments
  3. Otsuka America Pharmaceutical, Inc. $556 34 payments
  4. Takeda Pharmaceuticals U.S.A., Inc. $503 28 payments
  5. Tris Pharma Inc $382 22 payments
  6. Lundbeck LLC $292 15 payments
  7. Bausch Health US, LLC $251 24 payments
  8. Janssen Pharmaceuticals, Inc $248 6 payments
  9. ITI, Inc. $247 13 payments
  10. Ironshore Pharmaceuticals Inc. $220 13 payments
  11. Other $1,794 99 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $5,636 320 payments
  2. Education $113 2 payments
Products named General payments · program years 2021–2025
  1. Auvelity $694 33 payments
  2. TRINTELLIX $503 28 payments
  3. REXULTI Psychiatry $447 28 payments
  4. VRAYLAR $447 29 payments
  5. Dyanavel XR $359 20 payments
  6. REXULTI Psychiatry $292 15 payments
  7. WELLBUTRIN $251 24 payments
  8. APLENZIN $251 24 payments
  9. Azstarys $215 12 payments
  10. CAPLYTA $212 11 payments
  11. Other $2,903 149 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 12 drugs

Part D claims

222

Median for Nurse Practitioner: 389

Drug cost

$4,628

Median for Nurse Practitioner: $21,885

Branded share of claims

18.9%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Lurasidone Hcl Generic 17 $1,390
Bupropion Xl Bupropion Hcl Brand 13 $538
Trazodone Hcl Generic 22 $537
Quetiapine Fumarate Generic 15 $421
Alprazolam Generic 24 $392
Bupropion Hcl Sr Bupropion Hcl Brand 29 $370
Escitalopram Oxalate Generic 28 $278
Gabapentin Generic 16 $180
Methylphenidate Hcl Generic 13 $175
Fluoxetine Hcl Generic 17 $158

The 10 drugs with the highest cost, of 12 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 11 billing codes

Paid by Medicare

$4,172

Medicare's payments for the services billed

Medicare patients

30

Average age 69

Services billed

52

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Depression 75%
Arthritis 60%
Diabetes 43%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 24 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
REXULTI
  • Otsuka America Pharmaceutical, Inc. $220
  • Lundbeck LLC $62
$282 — —
Auvelity
  • Axsome Therapeutics, Inc. $214
$214 — —
TRINTELLIX
  • Takeda Pharmaceuticals U.S.A., Inc. $187
$187 — —
Azstarys
  • Corium, Inc. $109
$109 — —
Dyanavel XR
  • Tris Pharma Inc $105
$105 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 24 in the dashboard with a free account

Records

322 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Psychiatric/Mental Health in Delaware

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record